EMA Withdrawn: Iblias (octocog alfa) — Bayer AG

View source ↗

Summary

The EMA lists Iblias (octocog alfa) as Withdrawn; the therapeutic area is Hemophilia A and the marketing authorization holder is Bayer AG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• IbliaS (octocog alfa)

Snippet

Status: Withdrawn. Therapeutic area: Hemophilia A. MAH: Bayer AG. Decision date: 10/11/2017